Leveraging proteomic data alongside genomic, metabolomic, and other health information, PrognomiQ aims to transform disease detection and treatment. Their test products enable medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases. By overcoming technical and economic barriers, they tap into the untapped potential of proteomics for clinical purposes. Complementing proteomics with genomics and other data, their multi-omics platform generates powerful insights for early-stage disease detection and treatment. PrognomiQ's proprietary platform incorporates the Proteograph technology platform from Seer, a life science tools company.